Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 268

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Treatment of solid organ transplant recipients with autologous Epstein Barr virus–specific cytotoxic T lymphocytes (CTLs)

Open access
Savoldo, Barbara, Goss, John A., Hammer, Markus M., Zhang, Lan, Lopez, Teresita, Gee, Adrian P., Lin, Yu-Feng, Quiros-Tejeira, Ruben E., Reinke, Petra, Schubert, Stephan, Gottschalk, Stephen, Finegold, Milton J., Brenner, Malcolm K., Rooney, Cliona M., Heslop, Helen E. · 2006 · Blood

Abstract

We have investigated the in vivo safety, efficacy, and persistence of autologous Epstein Barr virus (EBV)–specific cytotoxic T lymphocytes (CTLs) for the treatment of solid organ transplant (SOT) recipients at high risk for EBV-associated posttransplantation lymphoproliferative disease (PTLD). EBV-CTLs generated from 35 patients expanded with normal kinetics contained both CD8 and CD4 lymphocytes and produced significant specific killing of autologous EBV-transformed B lymphoblastoid cell lines (LCLs). Twelve SOT recipients at high risk for PTLD, or with active disease, received autologous CTL infusions without toxicity. Real-time polymerase chain reaction (PCR) monitoring of EBV-DNA showed a transient increase in plasma EBV-DNA suggestive of lysis of EBV-infected cells, although there was no consistent decrease in virus load in peripheral-blood mononuclear cells. Interferon-γ enzyme-linked immunospot (ELISPOT) assay and tetramer analysis showed an increase in the frequency of EBV-responsive T cells, which returned to preinfusion levels after 2 to 6 months. None of the treated patients developed PTLD. One patient with liver PTLD showed a complete response, and one with ocular disease has had a partial response stable for over one year. These data are consistent with an expansion and persistence of adoptively transferred EBV-CTLs that is limited in the presence of continued immunosuppression but that nonetheless produces clinically useful antiviral activity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2006-05-021782

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 268

Metadata

Authors
Savoldo, B., Goss, J. A., Hammer, M. M., Zhang, L., Lopez, T., Gee, A. P., Lin, Y.-F., Quiros-Tejeira, R. E., Reinke, P., Schubert, S., Gottschalk, S., Finegold, M. J., Brenner, M. K., Rooney, C. M., & Heslop, H. E.
Venue
Blood
Published
2006-11-01
Volume
108
Issue
9
Pages
2942-2949
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2089297905
Cited by
268
References
18
FWCI
10.70
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment of solid organ transplant recipients with autologous Epstein Barr virus–specific cytotoxic T lymphocytes (CTLs). https://app.cochat.ai/papers/10.1182/blood-2006-05-021782
The paper
Savoldo, B., Goss, J. A., Hammer, M. M., Zhang, L., Lopez, T., Gee, A. P., Lin, Y.-F., Quiros-Tejeira, R. E., Reinke, P., Schubert, S., Gottschalk, S., Finegold, M. J., Brenner, M. K., Rooney, C. M., & Heslop, H. E. (2006). Treatment of solid organ transplant recipients with autologous Epstein Barr virus–specific cytotoxic T lymphocytes (CTLs). Blood. https://doi.org/10.1182/blood-2006-05-021782

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.